Medivir (MVIR) Pareto Securities Healthcare Conference presentation summary

Unmet medical need and market opportunity

• Advanced liver cancer (HCC) has significant unmet needs in second-line treatment, with no approved options currently available and a rapidly growing patient population driven by increases in fatty liver disease and improved first-line therapies.

• The global second-line HCC market is projected to exceed $4 billion by 2030, with substantial growth in the US and China.

Fostrox mechanism and clinical profile

• Fostrox is an oral, liver-targeted therapy that combines two mechanisms to selectively induce DNA damage in tumor cells while sparing healthy liver tissue.

• The drug remains inactive until reaching the liver, where it is activated by liver enzymes, maximizing local exposure and minimizing systemic side effects.

• Clinical studies show fostrox plus lenvatinib achieves a median time to progression (TTP) of 10.9 months, outperforming lenvatinib monotherapy and other second-line treatments.

• The combination demonstrates a 24% overall response rate and 81% disease control rate, with over 75% of patients experiencing tumor shrinkage.

Safety and tolerability

• Long-term use is supported by stable neutrophil and platelet counts throughout treatment.

• Liver function remains stable during therapy, with no deterioration in liver enzymes observed.

• The combination of fostrox and lenvatinib is well tolerated, enabling extended treatment durations.